Evoke Pharma, Inc. Announces Board Changes
May 03, 2019 at 05:01 pm EDT
On May 2, 2019, Scott L. Glenn resigned from the Board of Directors of Evoke Pharma, Inc. In addition, the Board has determined to reassign Todd Brady, M.D., Ph.D. from Class I of the Board to Class II of the Board and, accordingly, Dr. Brady will stand for re-election at the 2021 Annual Meeting of Stockholders. Further, the Board appointed Dr. Brady as a member of the Audit Committee to replace Mr. Glenn as an Audit Committee member.